High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C.
about
Clinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States.Low prevalence of liver-kidney microsomal autoantibodies of type 1 (LKM1) in hepatitis C seropositive subjects on Crete, GreeceAutoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the diseaseActivation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders.Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine modelPrevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohortAutoantibody prevalence in children with liver disease due to chronic hepatitis C virus (HCV) infectionPeripheral B-cell CD5 expansion and CD81 overexpression and their association with disease severity and autoimmune markers in chronic hepatitis C virus infectionProteinase 3 and dihydrolipoamide dehydrogenase (E3) are major autoantigens in hepatitis C virus (HCV) infectionAutoantibodies in chronic hepatitis C: A clinical perspectiveAnticardiolipin antibodies in patients with chronic hepatitis C virus infection: characterization in relation to antiphospholipid syndromeChronic hepatitis C virus infection: prevalence of extrahepatic manifestations and association with cryoglobulinemia in Bulgarian patients.Management of thrombocytopenia in advanced liver diseaseVerification of B-lymphocyte activating factor's involvement in the exacerbation of insulin resistance as well as an autoimmune response in patients with nonalcoholic steatohepatitis and patients with HCV-related chronic liver diseaseSerum Biomarkers for Discrimination between Hepatitis C-Related Arthropathy and Early Rheumatoid Arthritis.Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-alphaA new approach for treatment of hepatitis C in hepatitis C-autoimmune hepatitis overlap syndrome.Autoimmune hepatitis and its variant syndromes.Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: a pilot studyClinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection.Understanding the presence of false-positive antibodies in acute hepatitisAutoantibodies in Chinese patients with chronic hepatitis B: prevalence and clinical associations.Assessment of the Frequency of Autoantibodies in Chronic Viral Hepatitis.Management of chronic hepatitis C.Cryoglobulins are not essentialCryoglobulinaemia and rheumatic manifestations in patients with hepatitis C virus infectionHepatitis C virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of hepatitis C virus infectionRituximab-based treatment, HCV replication, and hepatic flares.Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection.Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature.Serological markers of autoimmunity in patients infected with hepatitis C virus: impact of HIV co-infection.Antiviral treatment down-regulates peripheral B-cell CD81 expression and CD5 expansion in chronic hepatitis C virus infectionAutoantibodies and autoimmune disease during treatment of children with chronic hepatitis C.Retinopathy and Uveitis Associated with Sofosbuvir Therapy for Chronic Hepatitis C Infection.Long-term serologic follow-up of isolated hepatitis B core antibody in HIV-infected and HIV-uninfected women.Anti-rods/rings autoantibody seropositivity does not affect response to telaprevir treatment for chronic hepatitis C infection.Study of non-organ-specific antibodies in children with genotype 4 chronic hepatitis C.Host factors determining the efficacy of hepatitis C treatment.Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis.Autoantibodies in liver disease: important clues for the diagnosis, disease activity and prognosis.
P2860
Q24791398-39EAD22F-2521-4AF5-9379-3F55F033A2CBQ24799970-5584160E-4AFE-4289-97E5-C51CB4C88653Q24804699-3EF50FAA-0A41-4FFE-B533-FD2A47AECB43Q27472760-034C759C-D1D3-4EA6-9B39-32E22C83876DQ27472895-79B89717-BC53-419C-8D3B-D872293060DAQ27477841-5A240CE4-3655-4DA0-BB91-94BCD67EFBF0Q27480424-9DED31F9-4188-43E8-8975-98F8FBDB6684Q27480668-1D5C278E-4A4B-4E28-B864-38A9D80F0276Q27480696-A7648249-E0E9-45BA-81D7-5AFC330B6C25Q28088556-117D7000-6855-4BEA-9568-709712F5F7C2Q33331690-151F4962-F262-4F6F-9956-688A3074A198Q33378075-A1572C6F-8D9F-4CF1-958C-4E24E8DCE8E2Q33417667-6C71A99A-5827-42EE-B6A3-81F530837A28Q33795637-3A7EDB84-1E7F-461E-B839-E3EB8A1ECB0CQ33839099-3A20FDD3-A310-4D4A-9650-4F8E5AC19585Q33909777-89BB7B54-A934-4A6E-BDF9-0DE90E38CA9AQ33916375-39859DCA-8084-479E-A2CC-8CE868592C2EQ34371115-CA4764C1-D0AB-4404-87CD-16C1A075E051Q34605699-E92579D4-812F-443D-998F-A1E26712751FQ34626547-2A9BD185-BF5B-455B-902D-BA6F55AF96A3Q34736038-B8B30546-C5FC-4C24-9CF1-4508C88EA3C3Q34827471-9D93DF17-1A1C-4BE2-BD4A-5BE9754CEB14Q35277469-FCD51AC1-0EDD-422A-B567-2A572B64047FQ35522138-90CADAFD-E30E-4C16-BA91-406B64DDB5BFQ35547463-D986BDCC-2354-4B3C-9D2D-2F2AD3D5B4CFQ35547638-AB4B7E80-B038-4086-A87B-F57C5C3E187AQ35731058-C7B36EDD-561A-4BC2-9E93-FA812924A841Q36167378-6C4BC233-6EBF-4642-8879-663932123EAFQ36231193-405745F1-AC82-4A10-AC57-2973B121920CQ36300105-89041F0B-EABB-452D-AC27-B311E69602FBQ36305824-EB2B516F-4939-4975-8448-7A0E38A59DC5Q36524424-F394B1AB-2D10-4C81-B1F2-898711D71F2FQ36641415-B581298A-3C80-4884-BEF3-4429C3CDB98BQ36974151-7202F0F6-248E-4795-A7C7-1D7C49F185F0Q37345473-BDE71BF2-E3C3-4465-8C7D-F733BC05BC62Q37413335-818B72FA-DA1C-4069-9A35-0F940042EA61Q37645723-F23E0966-D8A2-46B0-A77B-D5C22360D66AQ38056077-F09F86F7-50ED-49FF-8736-F3DE96070F72Q38368635-C93E1A20-ACF8-4079-A614-F0AEE869490CQ38497449-8FF5B02F-F22A-44A5-808E-17FF3E9E440D
P2860
High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
High prevalence of serological ...... ents with chronic hepatitis C.
@en
type
label
High prevalence of serological ...... ents with chronic hepatitis C.
@en
prefLabel
High prevalence of serological ...... ents with chronic hepatitis C.
@en
P2093
P1433
P1476
High prevalence of serological ...... ents with chronic hepatitis C.
@en
P2093
Bonkovsky HL
Clifford BD
P304
P356
10.1016/0270-9139(95)90507-3
P407
P577
1995-03-01T00:00:00Z